Royalty Pharma RPRX Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $630.58M+1.4% | $621.99M+2.1% | $609.29M+5.3% | $578.67M+1.8% | $568.25M-4.3% | ||
| $39.79M-21.2% | $50.5M0.0% | $50.5M-83.2% | $300.5M+495% | $50.5M+10,000% | ||
| $159.49M-2.9% | $164.27M+38.4% | $118.73M-34.0% | $179.77M+62.4% | $110.71M+63.8% | ||
| $69.44M— | —— | —— | —— | $0— | ||
| $67.54M-71.1% | $233.61M+28.3% | $182.14M-50.6% | $368.87M+983% | $34.07M-85.3% | ||
| $563.04M+45.0% | $388.38M-9.1% | $427.16M+104% | $209.8M-60.7% | $534.18M+47.8% | ||
| 89.3%+26.8pp | 62.4%-7.7pp | 70.1%+33.9pp | 36.3%-57.7pp | 94%+33.1pp | ||
| $93.72M-0.5% | $94.17M+18.4% | $79.56M+15.9% | $68.67M+5.2% | $65.26M-0.8% | ||
| $6.23M-11.9% | $7.07M+2.4% | $6.9M-17.1% | $8.33M-26.2% | $11.29M+24.9% | ||
| -$94.78M-192% | -$32.47M-290% | $17.06M+114% | -$119.16M-19.5% | -$99.75M— | ||
| $21.76M+443% | $4.01M-74.9% | $15.95M+492% | $2.69M-58.2% | $6.44M-79.6% | ||
| $468.26M+31.6% | $355.91M-19.9% | $444.21M+390% | $90.64M-79.1% | $434.43M+29.9% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $294.69M+37.6% | $214.21M-25.7% | $288.22M+855% | $30.18M-87.4% | $239.35M+15.0% | ||
| 46.7%+12.3pp | 34.4%-12.9pp | 47.3%+42.1pp | 5.2%-36.9pp | 42.1%+7.0pp | ||
| $0.67+34.0% | $0.50-25.4% | $0.67+857% | $0.07-87.3% | $0.55+17.0% | ||
| $0.67+34.0% | $0.50-25.4% | $0.67+857% | $0.07-87.3% | $0.55+17.0% | ||
| 556.8M-1.3% | 564.5M+0.9% | 559.6M-0.5% | 562.3M-2.7% | 578.1M-2.7% | ||
| 436.8M+1.6% | 429.8M-0.5% | 431.9M+2.0% | 423.5M-2.7% | 435.5M-2.8% | ||
| -$3.7M— | $0-100% | $766K-99.2% | $92.54M— | $0— | ||
| -$20.17M— | —— | $18.86M+162% | -$30.55M+33.4% | -$45.88M— | ||
| -$6.68M-128% | $24.08M-54.1% | $52.48M+291% | -$27.42M-736% | -$3.28M-106% | ||
| $3.72M— | —— | —— | —— | $13.4M— | ||
| $6.23M-11.9% | $7.07M+2.4% | $6.9M-17.1% | $8.33M-26.2% | $11.29M+24.9% | ||
| $173.53M+2,497% | $6.68M-94.9% | $129.99M+16,231% | $796K-99.4% | $138.82M+17,145% | ||
| -$272.67M+9.0% | -$299.6M— | —— | -$507.81M+46.1% | -$941.3M— | ||
| -$477.87M+43.6% | -$847.8M+11.5% | -$958.31M-207% | -$311.98M-162% | $503.92M+200% | ||
| $718.23M-13.2% | $827.15M+17.7% | $702.62M+93.0% | $363.98M-38.9% | $596.08M-19.7% | ||
| -$2.2M+73.1% | -$8.17M-419% | -$1.58M-2.1% | -$1.54M+49.6% | -$3.06M-39.9% | ||
| $50.1M-37.8% | $80.54M-45.0% | $146.49M-49.8% | $291.57M-58.9% | $708.78M+1,247% | ||
| $452.37M-38.3% | $733.69M-23.7% | $961.87M+86,244% | $1.11M+5.4% | $1.06M-99.8% | ||
| $42.31M+747% | $4.99M+452% | $905K-98.6% | $62.99M+73.7% | $36.26M+1,018% | ||
| $4.32M+50.0% | $2.88M0.0% | $2.88M0.0% | $2.88M-77.1% | $12.59M0.0% | ||
| -$197.49M— | $0-100% | $12.14M+106% | -$203.94M-60.4% | -$127.14M-178% | ||
| $563.04M+45.0% | $388.38M-9.1% | $427.16M+104% | $209.8M-60.7% | $534.18M+47.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Royalty Pharma's revenue?
- Royalty Pharma (RPRX) generated $2.4B in revenue over the trailing twelve months, up 7.8% year over year.
- Is Royalty Pharma profitable?
- Royalty Pharma reported $827.3M in net income over the trailing twelve months, a 33.9% net margin.
- What is Royalty Pharma's earnings per share?
- Royalty Pharma's diluted EPS over the trailing twelve months is $1.91.
- Where does Royalty Pharma's income statement data come from?
- Every line is extracted from Royalty Pharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
